ACR Convergence 2025

October 24-29, 2025. Chicago, Illinois.

View by Number View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 0989

Human MAIT cell produce IL-17 independently of IL-23 and TL1A
Abstract Number: 1805

Human meniscus histopathological and transcriptomic changes at early and advanced stages of knee osteoarthritis
Abstract Number: 2220

Human Milk Fatty Acid Profiles Among Breastfeeding Mothers With and Without Systemic Autoimmune Rheumatic Diseases
Abstract Number: 0659

Human papillomavirus infection and systemic lupus erythematosus under biologic therapy: a retrospective analysis in a multicenter cohort
Abstract Number: 0704

Human Pharmacokinetics of Inhaled Liposomal Iloprost Support a Dosing Regimen for Treating Systemic Sclerosis- Related Digital Ulcer
Abstract Number: 0924

Human Serum Albumin Co-Modified with Malondialdehyde-Acetaldehyde and Citrulline Bind Multiple Scavenger Receptors and Alter Cellular Morphology
Abstract Number: 1377

Humanistic Burden of Sjögren’s Disease: A Systematic Review of Treatment Efficacy on Health-Related Quality-of-Life
Abstract Number: 1475

Humoral immune responses to real-world recombinant zoster vaccination in systemic lupus erythematosus
Abstract Number: 2413

Hydroxychloroquine and Adverse Cardiovascular Outcomes in Pregnant Patients with Systemic Lupus Erythematosus
Abstract Number: 1570

Hydroxychloroquine and Disease Progression in Systemic Sclerosis: Insights from Antibody-Stratified Survival Analyses
Abstract Number: 2214

Hydroxychloroquine and Pregnancy Outcomes in Lupus: Results from a population-based cohort study
Abstract Number: 0232

Hydroxychloroquine Blood Testing in Lupus: The Michigan Medicine Experience
Abstract Number: 2459

Hydroxychloroquine Discontinuation in Systemic Lupus Erythematosus: A Retrospective Cohort Study with 3-Year Follow-Up
Abstract Number: 1524

Hydroxychloroquine Reduces Autoantibody Levels in Persons at Risk for Systemic Lupus Erythematosus
Abstract Number: 2444

Hydroxychloroquine-Induced Retinopathy in Systemic Lupus Erythematosus: Predictors of Progression Following Drug Discontinuation

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].